SKSuresh Kumar

Suresh Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Suresh Kumar has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)

    by Meenu Bajpai, Ashish Maheshwari, Vikas Dogra, Suresh Kumar, Ekta Gupta, Pratibha Kale, Vandana Saluja, Sherin S Thomas, Nirupama Trehanpati, Chhagan Bihari, et al.

    Importance: No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation. Objective: To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients. Design, setting and participants: A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group. Intervention: One group received COPLA with SMT (n=200), and another group received SMT only (n=200). Main outcome measures: Primary outcome was time to clinical improvement measured by a two-point reduction in the ordinal scale. Secondary outcomes included duration of O 2 therapy, the proportion of patients on mechanical ventilation at day-7, mortality, SARS-CoV-2 antibody levels, cytokine levels and incidence of adverse events. Results: The median time to a two-point reduction in the ordinal scale in both groups was 9 days (IQR=7–13) (p=0.328). The median duration of O 2 therapy was 8 days (IQR=6–12) in COPLA and 10 days (IQR=6–12) in SMT group (p=0.64). The PaO 2 /FiO 2 ratio showed significant improvement at 7 days in COPLA group(p=0.036). There was no difference in mortality till 28 days in both groups (p=0.62). However, if COPLA was given within 3 days of hospital admission, a significant reduction in ordinal scale was observed (p=0.04). Neutralising antibody titres in COPLA group (80 (IQR 80–80)) were higher than SMT group (0 (IQR 0–80)) at 48 hours (p=0.001). COPLA therapy led to a significant reduction in TNF-α levels at 48 hours (p=0.048) and D-dimer at 7 days (p=0.02). Mild allergic reactions were observed in 3 (1.5%) patients in COPLA group. Conclusion and relevance: Convalescent plasma with adequate antibody titres should be transfused in COVID-19 patients along with SMT in the initial 3 days of hospitalisation for better clinical outcomes. Trial registration number: NCT04425915 .


  • Open Access

    Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients

    by Meenu Bajpai, Ashish Maheshwari, Suresh Kumar, Karan Chhabra, Pratibha Kale, Ashad Narayanan, Amita Gupta, Ekta Gupta, Nirupama Trehanpati, Reshu Agarwal, et al.

    Background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease. Results: The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.


  • Open Access

    Sustained expression of inflammatory monocytes and activated T cells in COVID‐19 patients and recovered convalescent plasma donors

    by Ravinder Singh, Hamed Hemati, Meenu Bajpai, Pushpa Yadav, Ashish Maheshwari, Suresh Kumar, Sonal Agrawal, Jayesh Kumar Sevak, Mojahidul Islam, Jaswinder Singh Mars, et al.

    Introduction: Intense monocyte activation and infiltration into the target tissues are the main mechanisms of lung injury in severe acute respiratory syndrome coronavirus 2 infection. A reduction in the degree and nature of such cellular responses is expected following recovery. We aimed to investigate the immune responses in moderate coronavirus disease 2019 (COVID‐19) patients and recovered patients.Methods: Moderate COVID‐19 patients (n = 34) at Lok Nayak Hospital, New Delhi, and COVID‐19 recovered patients (n = 15) from the mild disease who were considered for convalescent plasma (COPLA) donation at the Institute of Liver and Biliary Sciences, New Delhi and healthy individuals (n = 10), were recruited. We have assessed 21 plasma cytokines using cytokine bead array, performed proteomics on serum proteins, and analyzed immune cells using a detailed multicolor flow cytometry.Results: A significant increase in inflammatory markers such as macrophage inflammatory protein (MIP)1‐α, monocyte chemotactic protein‐1, macrophage migration inhibitory factor, vascular endothelial growth factor‐A, and Leptin was observed in the moderate patients. Nonsurvivors additionally showed increased interleukin (IL)‐6 levels. Consistently, the proteomics analysis showed the signatures of cytokine production and interferon‐γ response, and increased level of acute‐phase protein SAA1 in the serum of COVID‐19 patients. Despite the sustained expression of MIPs, the recovered COPLA donors showed a surge in MCSF and IL‐18 levels. Both the groups had increased CCR2, CX3CR1 positive monocytes, low CD8+ T cells, A proliferation‐inducing ligand, and B‐cell activating factor receptor+ B cells compared with healthy subjects.Conclusions: Patients who have recovered and considered for COPLA donations still have compromised immunity with sustained expression of inflammatory monocytes and activated T cells.